The Technical Analyst
Select Language :
Spero Therapeutics Inc [SPRO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Spero Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Spero Therapeutics Inc is listed at the  Exchange

-0.57% $1.740

America/New_York / 28 mar 2024 @ 15:09


Spero Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 93.73 mill
EPS: 0.430
P/E: 4.05
Earnings Date: May 09, 2024
SharesOutstanding: 53.87 mill
Avg Daily Volume: 0.314 mill
RATING 2024-03-28
A
Buy
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Buy
Return On Asset: Strong Buy
DE: Neutral
P/E: Strong Buy
Price To Book: Neutral
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 4.05 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
0.69x
Company: PE 4.05 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 1.655 - 1.825

( +/- 4.89%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-02-01 Keutzer Timothy Buy 239 731 Common Stock
2024-02-02 Keutzer Timothy Sell 30 971 Common Stock
2024-02-02 Mahadevia Ankit Sell 63 795 Common Stock
2024-02-01 Joseph Tamara L Buy 239 731 Common Stock
2024-02-02 Joseph Tamara L Sell 30 906 Common Stock
INSIDER POWER
57.10
Last 96 transactions
Buy: 6 234 250 | Sell: 2 240 393

Forecast: 16:00 - $1.730

Live Trading Signals (every 1 min)

Forecast 1: 15:24 - $1.737
Forecast 2: 16:00 - $1.730
Forecast 3: 16:00 - $1.730
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.740 (-0.57% )
Volume 0.140 mill
Avg. Vol. 0.314 mill
% of Avg. Vol 44.53 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Spero Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Spero Therapeutics Inc

RSI

Intraday RSI14 chart for Spero Therapeutics Inc

Last 10 Buy & Sell Signals For SPRO

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Spero Therapeutics Inc

SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Last 10 Buy Signals

Date Signal @
CARTMar 28 - 15:1637.08
XRAYMar 28 - 15:14$33.28
MLKUSDMar 28 - 15:100.411
POOLXUSDMar 28 - 15:085.25
ABTUSDMar 28 - 15:081.940
HNTUSDMar 28 - 15:08$6.13
NTRSMar 28 - 15:05$88.62
DLTRMar 28 - 15:05$133.24
FSLRMar 28 - 15:04$168.29
FWONKMar 28 - 15:04$66.20

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.